Randomized controlled trial of concurrent hepatitis A and B vaccination

Area of Science:

• Immunology
• Vaccinology
• Preventive Medicine

Background:

• Hepatitis A virus (HAV) and Hepatitis B virus (HBV) pose significant health risks, particularly to deployed military personnel.
• Assessing the feasibility of simultaneous vaccination against both HAV and HBV is crucial for efficient immunization strategies.

Purpose of the Study:

• To determine the feasibility and immunogenicity of concurrent vaccination against Hepatitis A and Hepatitis B viruses.
• To evaluate local reactions associated with concurrent administration of Hepatitis A and Hepatitis B vaccines.

Main Methods:

• A randomized study involving 105 healthy adults (20-49 years) without prior HAV or HBV serologic markers.
• Participants received either inactivated Hepatitis A vaccine (HEP A), recombinant Hepatitis B vaccine (HEP B), or both concurrently.
• Vaccines were administered intramuscularly at 0, 1, and 6 months, with serologic testing at multiple time points.

Main Results:

• Concurrent vaccination demonstrated comparable antibody responses for both Hepatitis A and Hepatitis B compared to individual vaccinations.
• A higher incidence of mild injection site pain was reported at the Hepatitis B vaccination site when administered concurrently with Hepatitis A vaccine.
• High seroprotection rates (> or = 10 mIU/mL anti-HAV) were achieved by 1 month post-first dose and sustained through 12 months.

Conclusions:

• Concurrent vaccination with Hepatitis A and Hepatitis B vaccines is immunologically feasible in adults.
• Increased local pain at the Hepatitis B injection site is a notable, though generally mild, side effect of concurrent administration.
• Further research is recommended for combined vaccine development and approval for younger age groups.